Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), UnitedHealth (UNH) and Travere Therapeutics (TVTX)

Tipranks - Tue Feb 24, 11:16AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Butterfly Network (BFLYResearch Report), UnitedHealth (UNHResearch Report) and Travere Therapeutics (TVTXResearch Report).

Claim 50% Off TipRanks Premium

Butterfly Network (BFLY)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Butterfly Network today. The company’s shares closed last Monday at $2.91.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 34.1% and a 59.1% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Diamedica Therapeutics, and Fennec Pharmaceuticals. ;'>

Currently, the analyst consensus on Butterfly Network is a Strong Buy with an average price target of $5.00.

See Insiders’ Hot Stocks on TipRanks >>

UnitedHealth (UNH)

In a report issued on February 20, George Hill from Deutsche Bank maintained a Hold rating on UnitedHealth. The company’s shares closed last Monday at $283.45.

According to TipRanks.com, Hill is a 4-star analyst with an average return of 8.7% and a 53.1% success rate. Hill covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Molina Healthcare, and Elevance Health. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $368.50 average price target.

Travere Therapeutics (TVTX)

Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Travere Therapeutics on February 20. The company’s shares closed last Monday at $29.88.

Agrawal has an average return of 65.4% when recommending Travere Therapeutics. ;'>

According to TipRanks.com, Agrawal is ranked #2244 out of 12109 analysts.

Travere Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $42.73, representing a 43.2% upside. In a report issued on February 20, TipRanks – Google also upgraded the stock to Buy with a $33.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.